Hold the Presses is your online newsportal en brings press releases from around the world. Journalists can use it for free, although it is their responsibilty to check the news. Hold the Presses is in no way responsible for the content of the press releases, the Sender is. We hope you enjoy reading the news we bring you on this website. If a message is published that is not acceptable, we apologize. Please contact us and we will remove the message as soon as possible.

Thursday, 4 January 2018

Orion to renew operating model of its laboratories

Orion Oyj    


ORION CORPORATION                               PRESS RELEASE                4 JANUARY 2018 at 11.15        

Orion to renew operating model of its laboratories

 

Orion improves the competitiveness of its laboratory operations by renewing their operating model in Finland. As a result, the company will launch co-operation negotiations in the laboratory operations of pharmaceutical production, quality assurance and R&D in Espoo and Turku, and in Fermion's laboratories in Hanko, Espoo and Oulu. Orion Diagnostica's laboratories will not be part of the negotiations. The negotiations will affect all members of staff in all personnel groups at the above-mentioned laboratories. The goal of the negotiations is to further streamline the operating model for laboratories and develop productivity by changing the operating model.

 

The company has today issued a negotiation proposal, as laid down in the Finnish Act on Co-operation within Undertakings, on the reorganisation of operations, boosting of efficiency of operations and possible personnel reductions. The operational changes and reorganisations are anticipated to result in changes to responsibilities, transfers to new roles, transfers to different locations, changes to the terms of employment and possible layoffs.

 

The negotiations may result in personnel reductions of a maximum of 40 persons. The plan is to implement some of the possible personnel reductions through retirement and ending of fixed-term contracts. The company may also transfer persons affected by the negotiations to other roles in the group. Should redundancies occur, the employer would, according to a preliminary estimate, give notice during 2018.

 

                                               
Contact person:
Elina Koivu, Human Resources Manager, Orion Corporation
phone +358 10 426 3007

 

 

 

Publisher:

ORION CORPORATION

Communications

Orionintie 1A, FI-02200 Espoo

Homepage: www.orion.fi

 

 

Orion is a globally operating Finnish pharmaceutical company - a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion's pharmaceutical R&D are central nervous system (CNS) disorders, oncology and respiratory diseases for which Orion develops inhaled Easyhaler® pulmonary drugs. Orion's net sales in 2016 amounted to EUR 1,074 million and the company had about 3,500 employees. Orion's A and B shares are listed on Nasdaq Helsinki.

 





This announcement is distributed by Nasdaq Corporate Solutions (One Liberty Plaza, 165 Broadway, New York, NY 10006. Tel: +1 212 401 8700. www.nasdaqomx.com) on behalf of Nasdaq Corporate Solutions clients. Source: Orion Oyj, Orionintie 1, PL 65, Espoo 02101, Finland
If you would like to unsubscribe and stop receiving these e-mails click here.